Female Health Company targets India with grant:
This article was originally published in Clinica
The Female Health Company has won a £2 million ($2.9 million) grant from the UK government for manufacturing and marketing the female condom in India in a collaboration with Hindustan Latex. The Chicago-based company claims the product is the only device controleed by women that helps to prevent sexually-transmitted diseases, including HIV/AIDS. India has the second highest number of people living with HIV/AIDS, estimated at nearly four million, the company says.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.